Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up – Still a Buy?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $17.61, but opened at $19.76. Sarepta Therapeutics shares last traded at $22.2830, with a volume of 6,241,387 shares changing hands.

Trending Headlines about Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Early Phase 1/2 siRNA results point to target knockdown, muscle exposure and tolerability for SRP‑1001 and SRP‑1003 — the primary catalyst behind the rally. Business Wire: Sarepta Announces First Clinical Data
• Positive Sentiment: Multiple outlets and market commentators highlight the clinical readouts as a potential turning point; coverage helped drive heavy volume and momentum into the stock. Yahoo Finance: SRPT Stock Surges
• Positive Sentiment: Some sell‑side moves reflected renewed conviction — Morgan Stanley is reported to have raised its price target (reported widely alongside the trial coverage), which helped fuel the rally. InsiderMonkey: Morgan Stanley PT Hike
• Positive Sentiment: Unusually heavy options and call buying accompanied the move, indicating speculative bullish positioning and short‑term leverage from traders.
• Neutral Sentiment: Several valuation and note‑style writeups are trying to size the opportunity vs. risk — analysts and outlets caution that early Phase 1/2 data need confirmation and that valuation debate will drive near‑term swings. Yahoo/Zacks coverage: Is Further Upside Left?
• Negative Sentiment: Some firms remain skeptical — Citigroup raised a price target modestly but kept a sell rating (cites downside from current levels), and Needham reaffirmed an underperform stance, keeping sell‑side views polarized. Benzinga: Analyst Ratings
• Negative Sentiment: Independent analysts and commentators warn the data are early — some outlets argue it’s too soon to extrapolate durable clinical or commercial success from small Phase 1/2 cohorts. Seeking Alpha: Too Early to Get Excited
• Negative Sentiment: Underlying fundamentals and priorquarter results (recent EPS miss and revenue decline vs. year‑ago) remain a drag on sentiment; this increases the chance of volatility if follow‑up data or guidance disappoints.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on SRPT shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sarepta Therapeutics in a research note on Monday, December 29th. Royal Bank Of Canada increased their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a research note on Thursday, January 8th. Citigroup raised their price objective on shares of Sarepta Therapeutics from $9.00 to $13.00 and gave the stock a “sell” rating in a report on Thursday. Wells Fargo & Company cut their price objective on Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Finally, Mizuho upped their target price on Sarepta Therapeutics from $26.00 to $31.00 and gave the stock an “outperform” rating in a report on Thursday, March 12th. Nine analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have issued a Sell rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics has an average rating of “Hold” and a consensus target price of $32.30.

Sarepta Therapeutics Stock Down 8.8%

The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.48 and a current ratio of 2.32. The stock’s 50-day moving average price is $18.71 and its two-hundred day moving average price is $19.97. The stock has a market capitalization of $2.28 billion, a PE ratio of -2.57, a P/E/G ratio of 0.37 and a beta of 0.42.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing the consensus estimate of ($0.87) by ($2.71). Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The company had revenue of $442.93 million during the quarter, compared to the consensus estimate of $390.95 million. During the same period last year, the firm posted $1.90 earnings per share. The company’s revenue was down 32.7% compared to the same quarter last year. As a group, analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Insider Transactions at Sarepta Therapeutics

In related news, Director Stephen Mayo sold 7,239 shares of the stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $17.02, for a total transaction of $123,207.78. Following the sale, the director directly owned 1,765 shares of the company’s stock, valued at approximately $30,040.30. This represents a 80.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Kestra Advisory Services LLC purchased a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $25,000. iSAM Funds UK Ltd purchased a new position in Sarepta Therapeutics in the 3rd quarter worth approximately $25,000. Ancora Advisors LLC raised its holdings in Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 1,000 shares during the last quarter. Byrne Asset Management LLC bought a new position in Sarepta Therapeutics in the 3rd quarter valued at approximately $33,000. Finally, Allworth Financial LP lifted its position in Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 1,721 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.